Evidence map›Paper›PMID 24466322›Full record

ArticlePloS one2014

Human liver cell trafficking mutants: characterization and whole exome sequencing.

Fei Yuan, Erik L Snapp, Phyllis M Novikoff, Sylvia O Suadicani, David C Spray, Barry Potvin, Allan W Wolkoff, Pamela Stanley

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fei YuanMarion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Cell Biology, Albert Einstein College of Medicine, New York, New York, United States of America.
Erik L SnappMarion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, New York, New York, United States of America.
Phyllis M NovikoffMarion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Pathology, Albert Einstein College of Medicine, New York, New York, United States of America.
Sylvia O SuadicaniDepartment of Neuroscience, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Urology, Albert Einstein College of Medicine, New York, New York, United States of America.
David C SprayMarion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Neuroscience, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Medicine, Albert Einstein College of Medicine, New York, New York, United States of America.
Barry PotvinMarion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Cell Biology, Albert Einstein College of Medicine, New York, New York, United States of America.
Allan W WolkoffMarion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Medicine, Albert Einstein College of Medicine, New York, New York, United States of America.
Pamela StanleyMarion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, New York, United States of America ; Department of Cell Biology, Albert Einstein College of Medicine, New York, New York, United States of America.
Albert Einstein College of Medicine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Special Animal CoreP30DK041296 · NIDDK · YESHIVA UNIVERSITY · PI WOLKOFF, ALLAN W · 1989 to 2018
$22.9M
Project4: INTERACTION OF AUTOPHAGIC AND HETEROPHAGIC PATHWAYS IN LIVERP01DK041918 · NIDDK · YESHIVA UNIVERSITY · PI WOLKOFF, ALLAN W · 1990 to 2012
$19.1M
HEPATIC ORGANIC ANTION UPTAKE AND TRANSPORTR01DK023026 · NIDDK · YESHIVA UNIVERSITY · PI WOLKOFF, ALLAN W · 1986 to 2020
$7.8M
Control of vesicular trafficking in the hepatocyte.R01DK098408 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUERVO, ANA MARIA, WOLKOFF, ALLAN W · 2013 to 2022
$5.6M
NIDDK NIH HHS DK041296NIDDK NIH HHS DK041918NIDDK NIH HHS P01 DK041918NIDDK NIH HHS P30 DK041296NIDDK NIH HHS R01 DK023026
6 · The paper itself

Abstract

The HuH7 liver cell mutant Trf1 is defective in membrane trafficking and is complemented by the casein kinase 2α subunit CK2α''. Here we identify characteristic morphologies, trafficking and mutational changes in six additional HuH7 mutants Trf2-Trf7. Trf1 cells were previously shown to be severely defective in gap junction functions. Using a Lucifer yellow transfer assay, remarkable attenuation of gap junction communication was revealed in each of the mutants Trf2-Trf7. Electron microscopy and light microscopy of thiamine pyrophosphatase showed that several mutants exhibited fragmented Golgi apparatus cisternae compared to parental HuH7 cells. Intracellular trafficking was investigated using assays of transferrin endocytosis and recycling and VSV G secretion. Surface binding of transferrin was reduced in all six Trf2-Trf7 mutants, which generally correlated with the degree of reduced expression of the transferrin receptor at the cell surface. The mutants displayed the same transferrin influx rates as HuH7, and for efflux rate, only Trf6 differed, having a slower transferrin efflux rate than HuH7. The kinetics of VSV G transport along the exocytic pathway were altered in Trf2 and Trf5 mutants. Genetic changes unique to particular Trf mutants were identified by exome sequencing, and one was investigated in depth. The novel mutation Ile34Phe in the GTPase RAB22A was identified in Trf4. RNA interference knockdown of RAB22A or overexpression of RAB22AI34F in HuH7 cells caused phenotypic changes characteristic of the Trf4 mutant. In addition, the Ile34Phe mutation reduced both guanine nucleotide binding and hydrolysis activities of RAB22A. Thus, the RAB22A Ile34Phe mutation appears to contribute to the Trf4 mutant phenotype.

Indexed as

High-Throughput Nucleotide SequencingBlotting, WesternCarcinoma, HepatocellularCell CommunicationCells, CulturedEndocytosisExomeGap JunctionsHumansLiver NeoplasmsMutationProtein Transportrab GTP-Binding ProteinsReceptors, Cell SurfaceRNA, Small InterferingTransferrinrab GTP-Binding ProteinsReceptors, Cell SurfaceRNA, Small InterferingTransferrin

Identifiers

PMID24466322
PMCPMC3900707
OpenAlexW1985714236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.